MN58b (MN 58b bromide; MN58b; MN-58b) is a novel, potent and selective Choline kinase α (CHKα) inhibitor with anticancer activities.

NVP-CGM097 (also called CGM-097; CGM097; NVP-CGM-097; NVP CGM097) is a novel, highly potent, orally bioavailable and selective MDM2 ( (human homolog of double minute 2) inhibitor with antitumor activity.

A-1331852 (A1331852) is a potent and selective BCL-XL inhibitor with anticancer and immunomodulatory effects.

PD-1/PD-L1 Inhibitor 3 is a macrocyclic inhibitor of PD-1/PD-L1 protein-protein interaction.

RO8994, a spiroindolinone-based compound, is a novel, highly potent and selective small-molecule inhibitor of p53/MDM2 interaction with IC50 of 5 nM in a HTRF binding assay and 20 nM in a MTT proliferation assay.

BDA-366 (BDA366) is a potent and selective small-molecule antagonist of the Bcl2-BH4 domain with potential anticancer activity.

PRIMA-1 [also known as Prima-1; chemcial name, 2,2-Bis(hydroxymethyl)-3-quinuclidinone], a novel and potent small molecule compound which is the active form of APR-246 (also known as PRIMA-1MET), is a mutant p53 reactivator which induces apoptosis and inhibits growth of human tumors.

RG7112 (also known as RO5045337) is a novel, potent and highly selective antagonist/inhibitor of the p53-MDM2 protein-protein interaction with IC50 of 11 nM.

MI-773 (2’R,3S-isomer) (also known as MI773; SAR-405838; SAR405838), a spirooxindole analog, is a specific and orally bioavailable small molecule antagonist of MDM2-p53 protein‐protein interaction with antitumor activity.

HDM201 HCl (also called Siremadlin; NVP-HDM201, HDM stands for ‘human double minute 2 homolog’) is an orally bioavailable, highly potent and selective inhibitor of the p53-Mdm2 protein-protein interaction.